A new drug has been approved by the European Medicines Agency which could offer better treatment to patients with multiple sclerosis. Alemtuzumab will give people who have the disease the chance to live without the side effects for much longer.
Symptoms of the disease can include loss of physical skills, sensation, vision and bladder control.
Professor Herman Waldmann was involved in the early discovery work of the antibody drug called Campath-1H at Cambridge University. It was originally used to treat leukaemia. He continued to study the drug for two decades while at Oxford University.